biostudies-literatureUnknown13(1)Gaggiano C<h4>Introduction</h4>This study aims to explore awareness, knowledge, and diagnostic/therapeutic practices in monogenic uveitis (mU) among uveitis experts.<h4>Methods</h4>This is an explorative, cross-sectional survey study. An anonymous, semi-structured, electronic survey was delivered to uveitis experts from the Autoinflammatory Diseases Alliance (AIDA) Network and International Uveitis Study Group (IUSG). We included respondents answering ≥ 50% of the survey.<h4>Results</h4>Seventy-seven participants rated their knowledge of mU as proficient (3.9%), adequate (15.6%), sufficient (16.9%), or poor (63.6%). When asked about the first mU gene they thought of, 60.4% mentioned NOD2, 3.9% mentioned NLRP3 or MEFV, and 49.4% provided incorrect or no answers. Success rates in clinical scenarios vaOphthalmology and therapy127-147https://www.ebi.ac.uk/biostudies/studies/S-EPMC10776548biostudies-literatureKnowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA Network.PMC10776548Carreno EPleyer UGupta VCantarini LGaggiano CFrediani BTosi GMCunningham ETPavesio CEDenisova EVGoldstein Dde-la-Torre ABabu KYang PSobrin LDavis JLSridharan SFonollosa ADe Smet MDAgrawal RParoli MPFabiani CfalseKnowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA Network.<h4>Introduction</h4>This study aims to explore awareness, knowledge, and diagnostic/therapeutic practices in monogenic uveitis (mU) among uveitis experts.<h4>Methods</h4>This is an explorative, cross-sectional survey study. An anonymous, semi-structured, electronic survey was delivered to uveitis experts from the Autoinflammatory Diseases Alliance (AIDA) Network and International Uveitis Study Group (IUSG). We included respondents answering ≥ 50% of the survey.<h4>Results</h4>Seventy-seven participants rated their knowledge of mU as proficient (3.9%), adequate (15.6%), sufficient (16.9%), or poor (63.6%). When asked about the first mU gene they thought of, 60.4% mentioned NOD2, 3.9% mentioned NLRP3 or MEFV, and 49.4% provided incorrect or no answers. Success rates in clinical scenarios va2024-01-01T00:00:00Z2024 Jan2025-04-22T00:55:32.724Z2025-04-05T19:46:14.31ZS-EPMC107765483792448010.1007/s40123-023-00839-1